Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ITI-5000 |
| Synonyms | |
| Therapy Description |
ITI-5000 is a self-amplifying RNA vaccine that encodes the tumor-associated antigens HERV-K and CT-83, which potentially activates CD4+ and CD8+ T-cells to induce antitumor immune response (Journal for ImmunoTherapy of Cancer 2024:12). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ITI-5000 | ITI5000|ITI 5000 | ITI-5000 is a self-amplifying RNA vaccine that encodes the tumor-associated antigens HERV-K and CT-83, which potentially activates CD4+ and CD8+ T-cells to induce antitumor immune response (Journal for ImmunoTherapy of Cancer 2024:12). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07652242 | Phase I | ITI-5000 ITI-5000 + Pembrolizumab | First-in-human, Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) Alone or in Combination With Pembrolizumab in Stage II-- III Triple Negative Breast Cancer Following Standard Therapy ( VITAL-TNBC ) (VITAL-TNBC) | Recruiting | USA | 0 |